Aldeyra Therapeutics develops medicines for immune-mediated diseases. Lead product candidate reproxalap treats dry eye diseases in Phase III trials. Other products include ADX-629 for COVID-19, atopic asthma, psoriasis, and alcohol intoxication; ADX-2191 for retinitis pigmentosa and rare retinal diseases; ADX-246 for systemic immune-mediated disease; and ADX-248 for geographic atrophy. The company was previously Aldexa Therapeutics, Inc. before changing its name in 2014. It was incorporated in 2004 and is based in Lexington, Massachusetts.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.7 |